Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study

Basit Öğe Kaydı
dc.authorid0000-0002-3102-3315
dc.contributor.authorKocabas, Umut
dc.contributor.authorErgin, Isil
dc.contributor.authorYavuz, Veysel
dc.contributor.authorAltin, Cihan
dc.contributor.authorKaplan, Mehmet
dc.contributor.authorYilmaz Oztekin, Gulsum Meral
dc.contributor.authorTurk, Ugur Onsel
dc.date.accessioned2025-05-07T10:22:36Z
dc.date.available2025-05-07T10:22:36Z
dc.date.issued2024
dc.departmentEge Üniversitesi, Tıp Fakültesi, Dahili Bilimler Bölümü, Halk Sağlığı Ana Bilim Dalı
dc.description.abstractAims We aimed to determine the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting. Methods Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023. Results The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19-101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (P = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (P < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06-3.05; P = 0.027], higher household income (OR: 3.46; 95% CI: 1.27-9.42; P = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16-6.35; P = 0.021), diabetes (OR: 9.42; 95% CI: 6.72-13.20; P < 0.001), the use of angiotensin receptor-neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39-7.01; P < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49-2.75; P < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18-2.22; P = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30-2.29; P < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45-0.88; P = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37-0.76; P = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48-0.98; P = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49-0.91; P = 0.010) were independently associated with the non-use of SGLT2is. Conclusions The RED-HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.
dc.identifier.citationKocabas, U., Ergin, I., Yavuz, V., Altin, C., Kaplan, M., Oztekin, G. M. Y., Dogdus, M., Murat, S., Murat, B., Kivrak, T., Karabulut, D., Kaya, E., Ozdemir, I. H., Yildiz, C., Salkin, F. O., Ozcalik, E., Polatkan, S. G., Cakan, F., Sen, T., . . . Turk, U. O. (2025). Real-world data on empagliflozin and dapagliflozin use in patients with HEART failure: The RED-HEART study. ESC Heart Failure, 12(1), 434-446.
dc.identifier.doi10.1002/ehf2.15049
dc.identifier.endpage446
dc.identifier.issn2055-5822
dc.identifier.issue1
dc.identifier.pmid39340234
dc.identifier.scopus2-s2.0-85205077364
dc.identifier.scopusqualityQ1
dc.identifier.startpage434
dc.identifier.urihttps://doi.org/10.1002/ehf2.15049
dc.identifier.urihttps://hdl.handle.net/11454/117210
dc.identifier.volume12
dc.identifier.wosWOS:001321727100001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorErgin, Isil
dc.institutionauthorid0000-0002-3102-3315
dc.language.isoen
dc.publisherWiley Periodicals
dc.relation.ispartofESC Heart Failure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectguideline
dc.subjectheart failure
dc.subjectsodium–glucose cotransporter 2 inhibitors
dc.titleReal-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu